Podcast Summary

Podcast: Diabetes Connections | Type 1 Diabetes
Host: Stacey Simms
Episode: “I’m excited for less work for the person with diabetes” – An update from Medtronic’s Dr. Jennifer McVean
Guest: Dr. Jennifer McVean, Medical Affairs Director, Medtronic Diabetes
Date: October 7, 2025

Episode Overview

This episode dives deep into recent developments at Medtronic Diabetes, focusing on technological advances, new sensor rollouts, and real-world outcomes for users of the MiniMed 780G system. Dr. Jennifer McVean, a physician, leader at Medtronic, and person living with Type 1 diabetes, provides insights into their latest research, product development, global strategies, and her vision for reducing burden on people with diabetes. The tone balances clinical rigor with personal warmth, as Stacey and Dr. McVean share both data and lived experience.

Key Discussion Points & Insights

1. Dr. McVean’s Background and Advocacy for Access

• Dr. McVean is in Bogotá, Colombia, attending a Medtronic event with providers from Latin America, highlighting her bilingual skills and passion for expanding technology access, especially among Latino communities.
  • Quote: “One of my personal missions is to increase access to technology for all people and especially Latino individuals.” (07:45)

2. Medtronic’s Latest Real-World Outcomes Study (MiniMed 780G)

• Data Overview:
  • Three years of real-world data from Europe, the Middle East, and Africa on MiniMed 780G users 16+ years old
  • Glycemic control: Time in range improved from 60s baseline to 78.6% within one month and stayed stable over three years.
  • User burden: Studied the % of insulin doses given by system automation vs. user, and the decline in user-initiated boluses.
  • System trust: Evaluated recommended algorithm settings, including target adjustments and the importance of tight control.
  • Quote: “There hasn't been any data on any other system that has been published with data for that long of a period of time.” (09:38)
  • Tight glycemic targets now possible: MiniMed 780G allows settings down to 100 mg/dL, a shift from older systems with higher defaults.
  • Quote (on target settings): “We would actually be able to target 100 in a safe and effective manner...” (15:32)

3. The Evolution of Diabetes Technology and User Experience

• Personal Perspective:
  • Dr. McVean recalls living with diabetes since the 1980s—wiping meter strips, no CGMs, and running a marathon in medical school without CGM.
  • Quote: “I spent 13 hours traveling yesterday...when I got here I glanced at my pump and I was 100.” (20:08)
• Automation and Ease:
  • The MiniMed 780G’s autocorrection every 5 minutes and adaptable settings are “life-changing” for many.
  • Stacey expresses amazement at current debates about small differences in target ranges, given how far tech has come.

4. New Sensor Rollouts: Instinct by Abbott and Simplera Sync by Medtronic

• Expansion of Options:
  • Medtronic is now offering multiple sensor choices, each with easy insertions, no separate transmitters, longer wear, and proprietary system integration.
  • Instinct: 15-day wear; with the extended infusion set, users need as few as six insertions a month (“six pokes a month”).
  • Quote (on reduction in user burden): “With the MiniMed 780G with Instinct, about six pokes a month...That is what I am excited for. Less work for the person with diabetes.” (23:51)
• Real-World Data Includes New Sensors:
  • Some data from the European study already includes users of Simplera, demonstrating early adoption abroad.

5. Automated Insulin Delivery in Type 2 Diabetes

• MiniMed 780G is showing even better glycemic outcomes in people with Type 2 than in Type 1 (likely due to some preserved insulin secretion).
• System has features to make managing Type 2 easier:
  • 300-unit reservoirs, easy mid-week swaps, lengthy wear, and meal detection technology to cover missed or underestimated boluses.
  • Quote: “The system can kick in extra insulin...has that give and take...” (26:51)

6. What Healthcare Providers Want—Global Perspectives

• In Europe: Focus on clinical outcomes, time in range/A1C, patient health.
  • “They want to know what kind of outcomes does your system deliver...That is number one.” (30:21)
• In the United States: Balance between outcomes and ease—for both patients and staff, given busy practices.
  • “How is this easy for me and my staff?” (31:12)

7. Upcoming Product Naming & User-Centric Philosophy

• Medtronic moving away from numbers (e.g., 780G) to actual product names in response to user feedback.
  • Next hardware system is “slated for next year” and will have a name.
  • Quote: “Our next hardware, which is slated for next year, is going to have a name.” (11:51)
  • Rationale: Personalization, resonance with users, and a device that ‘fits into their lives.’
  • “We want it to be easy to use and something that they enjoy using, too.” (33:35)

8. Personal Reflections: Living with Diabetes

• Dr. McVean reflects on her 37 years with Type 1, gratitude for insulin’s discovery, and fulfillment as a physician/mother.
• Dreams of a future where new-onset children don't need lifelong insulin therapy.
  • Quote: “I believe in a day, I see a day where children who are diagnosed now with type 1 diabetes will no longer be on insulin. And I'm here for that day, too.” (36:40)
  • Encourages people to “try it again” with Medtronic’s newer, easier-to-use sensors: “Try it again. See what happens...” (38:07)

Memorable Quotes & Moments

| Timestamp | Quote | Speaker | |-----------|-------|---------| | 07:45 | “One of my personal missions is to increase access to technology for all people and especially Latino individuals.” | Dr. McVean | | 09:38 | “There hasn't been any data on any other system that has been published with data for that long of a period of time.” | Dr. McVean | | 11:51 | “Our next hardware, which is slated for next year, is going to have a name.” | Dr. McVean | | 15:32 | “We would actually be able to target 100 in a safe and effective manner...” | Dr. McVean | | 20:08 | “I spent 13 hours traveling yesterday...when I got here I glanced at my pump and I was 100.” | Dr. McVean | | 23:51 | “With the MiniMed 780G with Instinct, about six pokes a month...That is what I am excited for. Less work for the person with diabetes.” | Dr. McVean | | 26:51 | “The system can kick in extra insulin...has that give and take...” | Dr. McVean | | 30:21 | “They want to know what kind of outcomes does your system deliver...That is number one.” | Dr. McVean | | 33:35 | “We want it to be easy to use and something that they enjoy using, too.” | Dr. McVean | | 36:40 | “I believe in a day, I see a day where children who are diagnosed now with type 1 diabetes will no longer be on insulin. And I'm here for that day, too.” | Dr. McVean | | 38:07 | “Try it again. See what happens when you try one of the new sensors....give it a try.” | Dr. McVean |

Timestamps for Key Segments

• 06:14 – Dr. McVean’s introduction and global Medtronic outreach
• 08:05 – Podcast translation and medical content accuracy
• 09:31 – Overview of MiniMed 780G real-world outcomes study
• 12:31 – Study details: glycemic control, user burden, trust metrics (Europe/MEA)
• 15:23 – Lower target settings with 780G, technical explanation
• 16:53 – Time in tight range: next frontier in diabetes management
• 19:52 – Dr. McVean’s personal diabetes history and tech advances
• 21:11 – Sensor update: Instinct and Simplera overview, user impact
• 25:05 – Sensors included in study, new data upcoming
• 26:09 – MiniMed 780G for Type 2 diabetes, special considerations
• 29:50 – How much insulin is needed with pumps/automation?
• 30:08 – Provider questions: outcomes (Europe) vs. usability (U.S.)
• 32:11 – About naming vs. numbering of devices
• 34:20 – The importance of personalizing tech, comfort, and choice
• 36:00 – Dr. McVean reflects on her T1D journey and hopes for a cure
• 38:07 – Call to try Medtronic’s new sensors
• 40:05 – Discussion about attending community events and family/Caregiver issues
• 41:15 – Wrap-up and closing remarks

Themes & Tone

• Tone: Warm, optimistic, candid, occasionally humorous, with a strong blend of data-driven and personal anecdotes.
• Themes: Progress in diabetes technology, global access and disparities, ease and burden reduction, the importance of outcomes and personalization, hope for future cures, and the evolving identity of Medtronic/Minimed.

For Listeners

This episode will resonate with people living with T1D, parents, and caregivers who want to understand:

• How automated systems are changing daily diabetes management
• The importance of new sensor technology and user choice
• How Medtronic is responding to user needs (including naming/branding)
• Real-life expectations for system outcomes—and encouragement to revisit Medtronic if past experience was difficult

No prior technical knowledge is needed—Stacey Simms masterfully draws out Dr. McVean’s expertise to answer practical questions relevant to everyday diabetes management and future technology directions.

For additional information, check the show notes for links to Medtronic’s studies, sensor rollout details, past episodes, and community event registration.